{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:44:37Z","timestamp":1792615477501,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":582,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020968","name":"Boehringer Ingelheim Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020968","name":"Boehringer Ingelheim Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Client-owned diabetic cats (127 safety; 116 efficacy assessment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, randomized (1\u2009mg\/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in \u22651 clinical variable and \u22651 glycemic variable (margin \u0394: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On Day 45, 29\/54 (54%) velagliflozin-treated cats and 26\/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference \u221211.8%; upper 1-sided 97.5% confidence interval, \u2212\u221e to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was &amp;lt;252\u2009mg\/dL in 42\/54 (78%; velagliflozin) and 37\/62 (60%; Caninsulin); minimum BG was &amp;lt;162\u2009mg\/dL in 41\/54 (76%; velagliflozin) and 41\/62 (66%; Caninsulin); serum fructosamine was &amp;lt;450\u2009\u03bcmol\/L in 41\/54 (76%; velagliflozin) and 38\/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces\/diarrhea (n\u2009=\u200923\/61, 38%), positive urine culture (n\u2009=\u200919\/61, 31%), and nonclinical hypoglycemia (BG &amp;lt;63\u2009mg\/dL; n\u2009=\u20098\/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n\u2009=\u200935\/66, 53%), positive urine culture (n\u2009=\u200918\/66, 27%), and loose feces\/diarrhea (n\u2009=\u200910\/66, 15%). Diabetic ketoacidosis occurred in 4\/61 (7%; velagliflozin) and 0\/66 (Caninsulin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.17124","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:48:20Z","timestamp":1718606900000},"page":"2099-2119","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9667-6678","authenticated-orcid":false,"given":"Stijn J. M.","family":"Niessen","sequence":"first","affiliation":[{"name":"Veterinary Specialist Consultations & VIN Europe , Hilversum,","place":["The Netherlands"]},{"name":"Royal Veterinary College, University of London , Hertfordshire,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans S.","family":"Kooistra","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Utrecht University Department of Clinical Sciences, , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Forcada","sequence":"additional","affiliation":[{"name":"Veterinary Specialist Consultations & VIN Europe , Hilversum,","place":["The Netherlands"]},{"name":"Royal Veterinary College, University of London , Hertfordshire,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-1667","authenticated-orcid":false,"given":"Charlotte R.","family":"Bj\u00f8rnvad","sequence":"additional","affiliation":[{"name":"Bj\u00f8rnvad Consultancy , Vedb\u00e6k,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-4749","authenticated-orcid":false,"given":"Balazs","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Roessner","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Herberich","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Kroh","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2026020304084563100_jvim17124-bib-0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2022.105910","article-title":"Agreeing Language in Veterinary Endocrinology (ALIVE): diabetes mellitus\u2014a modified Delphi-method-based system to create consensus disease definitions","volume":"289","author":"Niessen","year":"2022","journal-title":"Vet J"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0002","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/jvim.14357","article-title":"What's in a name? Classification of diabetes mellitus in veterinary medicine and why it matters","volume":"30","author":"Gilor","year":"2016","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5326\/JAAHA-MS-6822","article-title":"AAHA diabetes management guidelines for dogs and cats","volume":"54","author":"Behrend","year":"2018","journal-title":"J Am Anim Hosp Assoc"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jfms.2007.10.013","article-title":"Treatment of 46 cats with porcine lente insulin\u2014a prospective, multicentre study","volume":"10","author":"Michiels","year":"2008","journal-title":"J Feline Med Surg"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0005","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jvim.15134","article-title":"Glucose concentrations after insulin-induced hypoglycemia and glycemic variability in healthy and diabetic cats","volume":"32","author":"Zini","year":"2018","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0006","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jfms.2009.04.010","article-title":"Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine","volume":"11","author":"Roomp","year":"2009","journal-title":"J Feline Med Surg"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0007","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1939-1676.2009.0342.x","article-title":"Cole C; PZIR clinical study group. Field safety and efficacy of protamine zinc recombinant human insulin for treatment of diabetes mellitus in cats","volume":"23","author":"Nelson","year":"2009","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1939-1676.2010.0579.x","article-title":"Evaluation of a quality-of-life tool for cats with diabetes mellitus","volume":"24","author":"Niessen","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0009","first-page":"27","article-title":"The big pet diabetes survey: perceived frequency and triggers for euthanasia","volume":"4","author":"Niessen","year":"2017","journal-title":"Vet Sci"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1939-1676.2004.tb00130.x","article-title":"Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats","volume":"18","author":"Nelson","year":"2004","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cvsm.2012.12.002","article-title":"Oral hypoglycaemics in cats with diabetes mellitus","volume":"43","author":"Palm","year":"2013","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0012","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2460\/javma.1997.210.06.772","article-title":"Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus","volume":"210","author":"Feldman","year":"1997","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304084563100_jvim17124-bib-0013","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0015","article-title":"SGLT2 inhibitors therapy protects glucotoxicity-induced \u03b2-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress","volume":"17","author":"Shyr","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0016","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00125-008-1201-y","article-title":"Hyperglycaemia but not hyperlipidaemia causes beta cell dysfunction and beta cell loss in the domestic cat","volume":"52","author":"Zini","year":"2009","journal-title":"Diabetologia"},{"key":"2026020304084563100_jvim17124-bib-0017","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ygcen.2013.04.029","article-title":"The effect of experimentally induced chronic hyperglycaemia on serum and pancreatic insulin, pancreatic islet ICF-I and plasma and urinary ketones in domestic cats (Felis felis)","volume":"118","author":"Link","year":"2013","journal-title":"Gen Comp Endocrinol"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0018","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jvp.12467","article-title":"Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats","volume":"41","author":"Hoenig","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0019","first-page":"52","article-title":"Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict","year":"2022","journal-title":"Can J Vet Res"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/jvim.16730","article-title":"Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus","volume":"37","author":"Hadd","year":"2023","journal-title":"J Vet Intern Med"},{"key":"2026020304084563100_jvim17124-bib-0021","first-page":"13","article-title":"Development and validation of a body condition score system for cats: a clinical tool","volume":"25","author":"Laflamme","year":"1997","journal-title":"Feline Pract"},{"key":"2026020304084563100_jvim17124-bib-0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1939-1676.2009.0435.x","article-title":"Quality matters: publishing in the era of CONSORT, REFLECT, and EBM","volume":"24","author":"Hinchcliff","year":"2010","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0023","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1098612X15571880","article-title":"ISFM consensus guidelines on the practical management of diabetes mellitus in cats","volume":"17","author":"Sparkes","year":"2015","journal-title":"J Feline Med Surg"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0024","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1098612X11434386","article-title":"Open-label trial of a multi-strain synbiotic in cats with chronic diarrhea","volume":"14","author":"Hart","year":"2012","journal-title":"J Feline Med Surg"},{"key":"2026020304084563100_jvim17124-bib-0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tvjl.2019.02.008","article-title":"International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats","volume":"247","author":"Weese","year":"2019","journal-title":"Vet J"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0026","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2460\/javma.230.7.1011","article-title":"Day-to-day variability of blood glucose concentration curves generated at home in cats with diabetes mellitus","volume":"230","author":"Alt","year":"2007","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0027","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1098612X17697482","article-title":"Prospective evaluation of a protocol for transitioning porcine lente insulin-treated diabetic cats to human recombinant protamine zinc insulin","volume":"20","author":"Gostelow","year":"2018","journal-title":"J Feline Med Surg"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0028","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jsap.13507","article-title":"One hundred years of insulin: is it time for smart?","volume":"63","author":"Gilor","year":"2022","journal-title":"J Small Anim Pract"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tvjl.2014.08.014","article-title":"Systematic review of feline diabetic remission: separating fact from opinion","volume":"202","author":"Gostelow","year":"2014","journal-title":"Vet J"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0030","first-page":"399","article-title":"Loose-control of diabetes mellitus with protamine zinc insulin in cats: 185 cases (2005\u20132015)","volume":"60","author":"Restine","year":"2019","journal-title":"Can Vet J"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0031","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40119-016-0069-z","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review","volume":"5","author":"Kalra","year":"2016","journal-title":"Cardiol Ther"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0032","first-page":"401","article-title":"SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment","volume":"60","author":"He","year":"2023","journal-title":"Acta Diabetol"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0033","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0034","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0036","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab"},{"key":"2026020304084563100_jvim17124-bib-0037","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/vec.12298","article-title":"Retrospective evaluation of risk factors and outcome predictors in cats with diabetic ketoacidosis (1997\u20132007): 93 cases","volume":"25","author":"Cooper","year":"2015","journal-title":"J Vet Emerg Critical Care"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0038","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-022-00528-7","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors and combined SGLT1\/2 inhibitors on cardiovascular, metabolic, renal, and safety outcomes in patients with diabetes: a network meta-analysis of 111 randomized controlled trials","volume":"22","author":"Teo","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.01.2720","article-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"126","author":"Nicolle","year":"2014","journal-title":"Postgrad Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0040","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0041","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1939-1676.2006.tb01797.x","article-title":"Frequency and risk factors for urinary tract infection in cats with diabetes mellitus","volume":"20","author":"Bailiff","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"4","key":"2026020304084563100_jvim17124-bib-0042","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1098612X19874141","article-title":"Subclinical bacteriuria in a mixed population of 179 middle-aged and elderly cats: a prospective cross-sectional study","volume":"22","author":"Moberg","year":"2020","journal-title":"J Feline Med Surg"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2099\/66662556\/jvim17124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2099\/66662556\/jvim17124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:09:18Z","timestamp":1770109758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/38\/4\/2099\/8448578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.17124","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2023-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}